Potential cardiac toxicity of H1-antihistamines

Histamine and H1-Antihistamines in Allergic Disease: Second Edition Revised and Expanded

Volumn , Issue , 2002, Pages 389-420

  Yap, Yee Guan ^a   Camm, A John ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0141927010     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (98)

1. Craft TM. Torsade de pointes after astemizole overdose. Br Med J 1986; 292:660.
2. Hoppu K, Tikanoja T, Tapanainen P, Remes M, Saarenpaa-Heikkila O, Kouvalainen K. Accidental astemizole overdose in young children. Lancet 1991; 338:538-540.
3. Clark A, Love H. Astemizole-induced ventricular arrhythmias: an unexpected cause of convulsions. Int J Cardiol 1991; 33:165-167.
4. Wiley II JF, Gelber ML, Henretig FM, Wiley CC, Sandhu S, Loiselle J. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992; 120:799-802.
5. Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. Br Med J 1989; 298:325.
6. MacConnell TJ, Stanners AJ. Torsades de pointes complicating treatment with terfenadine. Br Med J 1991; 302:1469.
7. Venturini E, Borghi E, Maurini V, Vecce R, Carnicelli A. Prolongation of the Q-T interval and hyperkinetic ventricular arrhythmias probably induced by terfenadine use in liver cirrhosis patients. Recenti Prog Med 1992; 83:21-22.
8. Simons FER, Kesselman MS, Giddins NG, Pelech AN, Simons KJ. Astemizole-induced torsade de pointes. Lancet 1988; 2:624.
9. Broadhurst P, Nathan AW. Cardiac arrest in a young woman with the long QT syndrome and concomitant astemizole ingestion. Br Heart J 1993; 70:469-470.
10. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264:2788-2790.
11. Zechnich AD, Hedges JR, Eiselt-Proteau D, Haxby D. Possible interactions with terfenadine or astemizole. West J Med 1994; 160:321-325.
12. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269:1532-1536.
13. Zhang M-Q. Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem 1997; 4:171-184.
14. Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic mechanism of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995; 122:701-714.
15. Priori SG, Barhanin J, Hauer RN, Haverkamp W, Jongsma HJ, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde AM. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation 1999; 99:674-681.
16. Colatsky TJ. Potassium channel modulators. Weston AH and Hamilton TC (eds). Oxford: Blackwell Scientific Publications, 304-340.
17. +current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96:195-215.
18. Sakmann B, Trube G. Conductance properties of single inwardly rectifying potassium channels in ventricular cells from guinea pig heart. J Physiol 1984; 347:641-657.
19. Rees S, Curtis MJ. Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias? Pharmacol Ther 1996; 69:199-217.
20. Berul CI, Morad M. Regulation of potassium channels by nonsedating antihistamines. Circulation 1995; 91:2220-2225.
21. 1antihistamines: a roundtable discussion. Schering-Plough Pharmaceuticals, Kenilworth, USA 1996, pp 22-31.
22. Ko CM, Ducic I, Fan J, Shuba YM, Morad M. Suppression of mammalian K+ channel family by ebastine. J Pharmacol Exp Ther 1997; 281:233-244.
23. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations: Role of M cells in the generation of U waves, triggered activity, and torsade de pointes. J Am Coll Cardiol 1994; 23:259-277.
24. El-Sherif N, Chinushi M, Caref EB, Restivo M. Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long-QT syndrome: detailed analysis of ventricular tridimensional activation patterns. Circulation 1997; 96:4392-4399.
25. Ks contributes to the longer action potential of the M cell. Circ Res 1995; 76:351-365.
26. Antzelevitch C, Davidenko JM, Sicouri S et al. Quinidine-induced early afterdepolarisation and triggered activity. J Electrophysiol 1989; 3:323-338.
27. Hii JTY, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992; 86:1376-1382.
28. Morganroth J. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms. Am J Cardiol 1993; 72:10B-13B.
29. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol 1993; 72:23B-25B.
30. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA1993; 270:2590-2597.
31. Roden DM. Torsade de pointes. Clin Cardiol 1993; 16:683-686.
32. Roy ML, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circ Res 1996; 94:817-823.
33. Surawicz B. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations. J Am Coll Cardiol 1989; 14:172-184.
34. Ducic I, Ko CM, Shuba Y, Morad M. Comparative effects of loratadine and terfenadine on cardiac K+ channels. J Cardiovasc Pharmacol 1997; 30:42-54.
35. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996; 385:77-80.
36. 1-receptor antagonist mizolastine on cardiac potassium and sodium currents. Allergy 1998; 53(Suppl. 43): 160.
37. Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacodynamic properties and therapeutic use in allergic disorders. Drugs 1994; 48:617-637.
38. 1-receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998; 54:113-121.
39. Lacerda AE, Roy M-L, Lewis EW, Rampe D. Interactions of the non-sedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart. Mol Pharmacol 1997; 52:314-322.
40. Weissenburger J, Noyer M, Cheymol G, Jaillon P. Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome. Clin Exp Allergy 1999; 29(Suppl. 3):190-196.
41. Yap YG, Camm AJ. The current cardiac safety situation with antihistamines. Clin Exp Allergy 1999; 29(Suppl. 1):15-24.
42. Tillement JP. A low distribution volume as a determinant of efficacy and safety for histamine (Hj)-antagonists. Allergy 1995; 50(Suppl. 24):12-16.
43. Leeson GA, Chan KY, Knapp WC, Biedenbach SA, Wright GJ, Okerholm RA. Metabolic disposition of terfenadine in laboratory animals. Arzneim-Forsch/Drug Res 1982; 32:1173-1178.
44. Michiels M, Van Peer A, Woestenborghs R, Heykants J. Pharmacokinetics and tissue distribution of astemizole in the dog. Drug Dev Res 1986; 8:53-62.
45. Simons FER, Murray HE, Simons KJ. Quantitation of Hj-receptor antagonists in skin and serum. J Allergy Clin Immunol 1995; 95:759-764.
46. Wang WX, Ebert SN, Liu XK, Chen YW, Drici MD, Woosley RL. ‘Conventional’ antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts. J Cardiovasc Pharmacol 1998; 32:123-128.
47. Zareba W, Moss AJ, Rosero SZ, Hajj-Ali R, Konecki J, Andrews M. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol 1997; 80:1168-1173.
48. Krenzelok EP, Anderson GM, Mirick M. Massive diphenhydramine overdose resulting in death. Ann Emerg Med 1982; 11:212-213.
49. Goetz CM, Lopez G, Dean BS, Krenzelok EP. Accidental childhood death from diphenhydramine overdosage. Am J Emerg Med 1990; 8:321-322.
50. Olson KR, Kearney TE, Dyer JE, Benowitz NL, Blanc PD. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1994; 12:392-395.
51. Hausmann E, Wewer H, Wellhoner HH, Weller JP. Lethal intoxication with diphenhydramine. Report of a case with analytical follow-up. Arch Toxicol 1983; 53:3339.
52. Karch SB. Diphenhydramine toxicity: comparisons of postmortem findings in diphenhydramine-, cocaine-, and heroin-related deaths. Am J Forensic Med Pathol1998; 19:143-147.
53. Park-Matsumoto YC, Tazawa T. Neuroleptic malignant syndrome associated with diphenhydramine and diprophyllin overdose in a depressed patient. J Neurol Sci1999; 162:108-109.
54. Honig PK, Wortham DC, Zamani K, Connor DP, Mullin JC, Cantilena LR. Terfena-dine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269:1513-1518.
55. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36:233-252.
56. Hey JA, del Prado M, Kreutner W, Egan RW. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Arzneim-Forsch/Drug Res 1996; 46: 159-163.
57. Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy 1999; 29(Suppl 3):116-124.
58. Simons FER, Simons KJ. Clinical pharmacology of new histamine Hj-receptor antagonists. Clin Pharmacokinet 1999; 36:329-352.
59. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59:383-388.
60. Rau SE, Bend JR, Arnold MO, Tran LT, Spence JD, Bailey DG. Grapefruit juiceterfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther 1997; 61:401-409.
61. Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52:311-315.
62. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52:231-238.
63. Honig PK, Wortham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993; 53:630-636.
64. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, Ruskin J, Moye L. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability. Am Heart J 1996; 131:472-480.
65. Moss AJ, Chaikin P, Garcia JD, Gillen M, Roberts DJ, Morganroth J. A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy 1999; 29(Suppl 3):200-205.
66. Lorber R, Danzig M, Brannan M. Loratadine (L) does not affect QTc interval nor produce torsades de pointes type arrhythmias. Allergy 1997; 37:207.
67. Affrime MB, Lorber R, Danzig M, Cuss F, Brannan MD. Three month evaluation of electrocardiographic effects of loratadine in humans. Allergy 1993; 48(Suppl 16):29.
68. 1-antihis-tamine. Clin Exp Allergy 1999; 29(Suppl 3):206-211.
69. Sale ME, Barbey JT, Woosley RL, Edwards D, Yeh J, Thakker K, Chung M. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther1994; 56:295-301.
70. Pratt C, Brown AM, Rampe D, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl. Clin Exp All 1999; 29(Suppl 3):212-216.
71. Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999; 83:1451-1454.
72. Pinto YM, van Gelder IC, Heeringa M, Crijns HJ. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet 1999; 353:980.
73. DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 1999; 21:281-295.
74. Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin CC, Affrime MB. Evaluation of pharmacokinetic and electrocardiographic parameters following 10 days of concomitant administration of loratadine with ketoconazole. J Clin Pharmacol 1994; 34:1016.
75. Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin CC, Cayen MN, Affrime MB. Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 1995; 58:269-278.
76. Brannan MD, Affrime MB, Reidenberg P, Radwanski E, Lin CC. Evaluation of the pharmacokinetics and electrocardiographic pharmacokinetics of loratadine with concomitant administration of cimetidine. Pharmacother 1994; 14:347.
77. Paserchia LA, Hewett J, Woosley RL. Effects of ketoconazole on QTc. Clin Pharmacol Ther 1994; 55(abstr):146.
78. Cetirizine prescribing information. Physician’s Desk Reference®, 52nd ed., Mont-vale, NJ: Medical Economics Co., 1998; 2234-2236.
79. Lindquist M, Edwards IR. Risks of non-sedating antihistamines. Lancet 1997; 349: 1322.
80. Cohen AT. Dangers of non-sedating antihistamines. Lancet 1997; 350:69-70.
81. Himmel MH, Honig PK, Worobec AS. Dangers of non-sedating antihistamines. Lancet 1997; 350:69-70.
82. Passalacqua G, Bousquet J, Bachert C, Church MK, Bindslev-Jensen C, Nagy L, Szemere P, Davies RJ, Durham SR, Horak F, Kontou-Fili K, Malling H-J, van Cauwenberge P, Canonica GW. The clinical safety of Hj-receptor antagonists. An EAACI position paper. Allergy 1996; 51:666-675.
83. Ahnve S. QT interval prolongation in acute myocardial infarction. Eur Heart J 1985; 6:D85-95.
84. Gottlieb SS, Cines M, Marshall J. Torsades de pointes with administration of highdose intravenous d-sotalol to a patient with congestive heart failure. Pharmacotherapy 1997; 17:830-831.
85. Martin AB, Garson A Jr, Perry JC. Prolonged QT interval in hypertrophic and dilated cardiomyopathy in children. Am Heart J 1994; 127:64-70.
86. Ramamurthy S, Talwar KK, Goswami KC, Shrivastava S, Chopra P, Broor S, Mal-hotra A. Clinical profile of biopsy proven idiopathic myocarditis. Int J Cardiol 1993; 41:225-232.
87. Ichida F, Fatica NS, O’Loughlin JE, Snyder MS, Ehlers KH, Engle MA. Correlation of electrocardiographic and echocardiographic changes in Kawasaki syndrome. Am Heart J 1988; 116:812-819.
88. Akiyama T, Batchelder J, Worsman J, Moses HW, Jedlinski M. Hypocalcemic torsades de pointes. J Electrocardiol 1989; 22:89-92.
89. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features; observations in 32 patients. J Am Coll Cardiol 1983; 2:806-817.
90. Curry P, Fitchett D, Stubbs W, Krikler D. Ventricular arrhythmias and hypokalae-mia. Lancet 1976; 2:231-233.
91. Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 1983; 68:846-856.
92. Kurita T, Ohe T, Marui N, Aihara N, Takaki H, Kamakura S, Matsuhisa M, Shimomura K. Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsades de pointes. Am J Cardiol 1992; 69:628-633.
93. Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, Bloch A. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J1992; 13:1002-1003.
94. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d, l-sotalol. Circulation 1996; 94:2535-2541.
95. Ebert SN, Liu XK, Woosley RL. Female gender as a risk for drug-induced cardiac arrhythmias: Evaluation of clinical and experimental evidence. J Womens Health1998; 7:547-557.
96. Smith SJ. Cardiovascular toxicity of antihistamines. Otolaryngol Head Neck Surg1994; 111:348-354.
97. Vukmir RB. Torsades de pointes: a review. Am J Emerg Med 1991; 9:250-255.
98. European Agency for the Evaluation of Medicinal Products. Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. March 1997 (CPMP/986/96).